

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Stephen Mark McAllister	)	Group Art Unit: 1615
	)	
Application No.: 10/060,849	)	Examiner: TRAN, SUSAN T
	)	
Filed: January 30, 2002	)	
	)	Confirmation No.: 9605
For: Pharmaceutical Formulation	)	
	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REVOCATION OF POWER OF ATTORNEY  
STATEMENT UNDER 37 C.F.R. § 3.73(b)  
AND GRANT OF NEW POWER OF ATTORNEY**

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in this patent application, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that **Capsugel Belgium BVBA** is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors to Smithkline Beecham PLC recorded in the U.S. Patent and Trademark Office at Reel 013013, Frame 0313, a change of name from Smithkline Beecham PLC to Smithkline Beecham Limited recorded at the U.S. Patent and Trademark Office at Reel 025113, Frame 0549, an assignment from Smithkline Beecham Limited to Pfizer, Inc. recorded in the U.S.

Patent and Trademark Office at Reel 025833, Frame 0373 and an assignment from Pfizer, Inc. to Capsugel Belgium BVBA recorded in the U.S. Patent and Trademark Office at Reel 026798, Frame 0043.


The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Customer Number 22,852, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please send all future correspondence concerning this application to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Dated:

October 12, 2011.

By: \_\_\_\_\_



Carl Mourisse  
Managing Director  
Capsugel Belgium BVBA